• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by SELLAS Life Sciences Group Inc.

    1/30/26 4:15:04 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    SELLAS Life Sciences Group, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    81642T209

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    81642T209


    1Names of Reporting Persons

    Highbridge Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6,514,658.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,514,658.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,514,658.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.7 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  The information set forth on this cover page reflects information as of the date hereof. The 6,514,658 shares of Common Stock (as defined in Item 2(a)) are issuable upon exercise of warrants reported herein. As of December 31, 2025, the Reporting Person may have been deemed to beneficially own 9,014,658 shares of Common Stock issuable upon exercise of warrants, representing 6.0% of the shares of Common Stock outstanding on such date.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SELLAS Life Sciences Group, Inc.
    (b)Address of issuer's principal executive offices:

    7 Times Square, Suite 2503, New York, NY 10036
    Item 2. 
    (a)Name of person filing:

    This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of SELLAS Life Sciences Group, Inc., a Delaware corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of the Reporting Person is 390 Madison Avenue, 28th Floor, New York, NY 10017.
    (c)Citizenship:

    Highbridge is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    81642T209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G as of December 31, 2025 is calculated based upon an aggregate of 142,442,239 shares of Common Stock outstanding as of November 11, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 12, 2025, and assumes the exercise of the warrants held by the Highbridge Funds. The percentage set forth in this Schedule 13G as of the date hereof is calculated based upon an aggregate of 170,282,026 shares of Common Stock outstanding as of January 7, 2026, as reported in the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 8, 2026, and assumes the exercise of the warrants held by the Highbridge Funds.
    (b)Percent of class:

    3.7%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Highbridge Capital Management, LLC
     
    Signature:/s/ Kirk Rule
    Name/Title:Kirk Rule, Executive Director
    Date:01/30/2026
    Get the next $SLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLS

    DatePrice TargetRatingAnalyst
    7/21/2021$18.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kalin Katherine Bach bought $100,806 worth of shares (63,400 units at $1.59), increasing direct ownership by 155% to 104,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    11/21/25 8:45:10 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/13/25 8:00:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wasman Jane bought $33,800 worth of shares (20,000 units at $1.69), increasing direct ownership by 192% to 30,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/2/25 4:42:07 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Varian John was granted 50,000 shares, increasing direct ownership by 218% to 72,900 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    1/9/26 4:43:43 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Van Nostrand Robert L was granted 50,000 shares, increasing direct ownership by 152% to 82,900 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    1/9/26 4:39:03 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Scheinberg David A was granted 50,000 shares, increasing direct ownership by 217% to 73,082 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    1/9/26 4:38:00 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SELLAS Life Sciences Group Inc.

    SCHEDULE 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    1/30/26 4:15:04 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

    1/8/26 8:30:35 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by SELLAS Life Sciences Group Inc.

    EFFECT - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

    11/26/25 12:15:31 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

    Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S. enrollment evaluating SLS009 in combination with AZA/VEN in newly diagnosed AML with high-risk features is planned for Q1 2026, with European enrollment anticipated in Q2 2026  NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into an agreement with IMPACT-AML, a European collaborative initiative dedicated t

    1/14/26 8:30:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Biopharma M&A is entering a fever pitch, with precision oncology investments alone exploding to $138 billion as major players scramble to secure proven cancer therapies before their most profitable drugs lose protection[1]. This looming $170 billion "patent cliff" has triggered a massive capital rotation into de-risked platforms that can reach patients and the market within the next 18 to 24 months[2]. This urgent race for registration-ready assets is driving the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), OS Therapies Inc. (NY

    1/8/26 12:08:13 PM ET
    $CELC
    $ONCY
    $RNXT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

    Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the final analysis is event-driven, and SELLAS will announce the occurrence of the 80th event NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided an update on the ongoing Phase 3 REGAL trial evaluating GPS as a potential maintenance therapy in patients with AML after second complete r

    12/29/25 8:35:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on SELLAS Life Sciences with a new price target

    Cantor Fitzgerald initiated coverage of SELLAS Life Sciences with a rating of Overweight and set a new price target of $18.00

    7/21/21 11:28:03 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital initiated coverage on Solaris Resources with a new price target

    RBC Capital initiated coverage of Solaris Resources with a rating of Outperform and set a new price target of $18.00

    6/21/21 6:52:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Financials

    Live finance-specific insights

    View All

    SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022

    NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reminds the investment community that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), including the potential commercial opportunity for GPS in AML patients. The conference call and webcast will be held on Thursday, September 15, 2022, from 1:00 p.m. to 2:00 p.m. ET featuring remarks from Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer, and Robert Francomano, Chief Commer

    9/8/22 8:00:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

    NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update. "During the third quarter of 2021, in addition to continuing to enroll patients in the United States and Europe for our Phase 3 REGAL study of galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients, we also commenced clinical and regulatory preparations for a potential new Phase 2/3 study of GPS in AML patients following a bon

    11/12/21 8:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

    Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia (AML) Patients Highlights Continued Unmet Need and Expanded Market Opportunity for GPS Cash Position of $29.9 million as of June 30, 2021 To Host Virtual Investor Symposium on GPS on August 17, 2021 NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad ran

    8/12/21 4:22:52 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SELLAS Life Sciences Group Inc.

    SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    11/8/24 8:33:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SELLAS Life Sciences Group Inc.

    SC 13G - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    2/7/24 3:01:47 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    2/16/21 10:08:07 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Leadership Updates

    Live Leadership Updates

    View All

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

    NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company's SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD. "We are thrilled to welcome Dr. Wang to our Scientific Advisory Board," said Dragan Cicic, MD, Senior Vice President, Chief Development Officer

    7/7/25 8:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations